575 related articles for article (PubMed ID: 31959349)
1. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
Mansfield AS; Każarnowicz A; Karaseva N; Sánchez A; De Boer R; Andric Z; Reck M; Atagi S; Lee JS; Garassino M; Liu SV; Horn L; Wen X; Quach C; Yu W; Kabbinavar F; Lam S; Morris S; Califano R
Ann Oncol; 2020 Feb; 31(2):310-317. PubMed ID: 31959349
[TBL] [Abstract][Full Text] [Related]
2. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab: A Review in Extensive-Stage SCLC.
Frampton JE
Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
[TBL] [Abstract][Full Text] [Related]
6. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L; Mansfield AS; Szczęsna A; Havel L; Krzakowski M; Hochmair MJ; Huemer F; Losonczy G; Johnson ML; Nishio M; Reck M; Mok T; Lam S; Shames DS; Liu J; Ding B; Lopez-Chavez A; Kabbinavar F; Lin W; Sandler A; Liu SV;
N Engl J Med; 2018 Dec; 379(23):2220-2229. PubMed ID: 30280641
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Goldman JW; Garassino MC; Chen Y; Özgüroğlu M; Dvorkin M; Trukhin D; Statsenko G; Hotta K; Ji JH; Hochmair MJ; Voitko O; Havel L; Poltoratskiy A; Losonczy G; Reinmuth N; Patel N; Laud PJ; Shire N; Jiang H; Paz-Ares L
Lung Cancer; 2020 Nov; 149():46-52. PubMed ID: 32961445
[TBL] [Abstract][Full Text] [Related]
8. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA
J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597
[TBL] [Abstract][Full Text] [Related]
9. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T
Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Zhou K; Zhou J; Huang J; Zhang N; Bai L; Yang Y; Li Q
Lung Cancer; 2019 Apr; 130():1-4. PubMed ID: 30885327
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E; Morgillo F; Garassino MC; Ciardiello F; Ardizzoni A; Stefani A; Verderame F; Morabito A; Chella A; Tonini G; Gilli M; Del Signore E; Berardi R; Mencoboni M; Bearz A; Delmonte A; Migliorino MR; Gridelli C; Pazzola A; Iero M; De Marinis F
Oncologist; 2024 May; 29(5):e690-e698. PubMed ID: 38377176
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab.
Bernabé R; Liu SV; Sánchez-Gastaldo A; Alonso García M
Oncol Ther; 2024 Mar; 12(1):175-182. PubMed ID: 38280181
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
[TBL] [Abstract][Full Text] [Related]
17. Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Lim JU; Kang HS; Shin AY; Yeo CD; Kim SK; Kim JW; Kim SJ; Lee SH
Thorac Cancer; 2022 Dec; 13(23):3384-3392. PubMed ID: 36274214
[TBL] [Abstract][Full Text] [Related]
18. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
